| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $2.2M | — | -65.6% |
| SG&A Expense | $1.8M | — | +30.7% |
| Operating Income | -$4.1M | — | +48.4% |
| Net Income | -$5.0M | — | +47.6% |
| EPS (Basic) | -$0.08 | — | +46.7% |
| EPS (Diluted) | -$0.08 | — | +46.7% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $14.1M | -20.4% | +89.9% |
| Current Assets | $15.7M | -19.3% | +69.0% |
| Total Assets | $15.8M | -19.3% | +65.4% |
| Current Liabilities | $7.3M | -9.0% | -93.4% |
| Total Liabilities | $146.0M | +0.2% | +19.9% |
| Stockholders' Equity | -$132.0M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$3.9M | — | +49.7% |
| Financing Cash Flow | $257K | — | — |
| -15.8% |